What's on

  • July 18, 2014

    IDIBAPS is the Spanish entity with more activities funded by the Innovative Medicines Initiative

    The report named "Spanish Participation in the Innovative Medicines Initiative (IMI)" has been recently published by the Center for Industrial Technological Development (CDTI). This report lists the main indicators of participation in 8 of the 11 IMI’s calls supported under the 7th Framework Programme.

    Read the rest of this entry

  • July 8, 2014

    IDIBAPS participates in the Graphene Flagship

    In the context of the Graphene Week 2014, the European Commission announced that the Graphene Flagship, one of the largest European research initiatives, is doubling its size and now includes more than 140 organizations from 23 countries. IDIBAPS is one of new 66 partners of the consortium through the team of Maria Victoria Sánchez-Vives, MD, PhD, ICREA Research Professor and team leader of the IDIBAPS group Systems Neuroscience. Professor Sanchez-Vives joins the Neurographene project, coordinated by Rosa Villa, PhD, from the CIBER-BBN Biomonitoring Group at the Barcelona Microelectronics Institute (IMB-CNM), and whose aim is to validate graphene as a brain interface material and to develop devices for both recording neural activity and for brain stimulation. The other partner in this project is the Austrian company Guger Technologies.

    Read the rest of this entry

  • July 3, 2014

    A mutation in progenitor cells identified as origin and therapeutic target for cholangiocarcinoma

    In recent years, cancer research has been focused on the identification of mutations in genes involved in tumor development. Nevertheless, the molecular pathways that contribute to the progression of the disease remain quite unknown. The journal Nature publishes a paper in which an international team of scientists, led by Nabeel Bardesy, PhD, from the Harvard Medical School, suggests that a mutation in the IDH enzyme (isocitrate dehydrogenase), that occurs in liver progenitor cells, promotes the progression of cholangiocarcinoma, a type of liver cancer. Josep M. Llovet, MD, PhD, ICREA Research Professor at the HCC Translational Research Lab of the Liver Unit at IDIBAPS and Director of Mount Sinai Liver Cancer Program at the Icahn School of Medicine at Mount Sinai (New York) has collaborated in the study together with Daniela Sia, PhD, and Helena Cornellà, members of the same research group.

    Read the rest of this entry

  • May 21, 2014

    An UB research shows that cholesterol plays a key role in cell migration

    A group of researchers led by professor Carles Enrich, Chief of  IDIBAPS' Endocytosis and Protein Intracellular Transit team and member of Cellular Biology, Immunology and Neurosciences UB Dept., have found that cholesterol plays a key role in cell mobility and tissue invasion. The results of the study prove that the accumulation of LDL cholesterol cells —the one carried by low-density lipoproteins— may play a crucial role in promoting cell mobility. On the contrary, high levels of HDL cholesterol —the one carried by high-density lipoproteins— may avoid cell propagation. This is a key study to better understand cancer metastasis, the process in which cancer cells invade healthy tissues, and foster the discussion on the relationship between cholesterol levels and cancer incidence. The paper is published in open access Cell Reports.

    Read the rest of this entry

  • April 7, 2014

    IDIBAPS researchers identified a new neurodegenerative disease related to sleep disorders

    Discover how the brain, memory, or what tools works allow you to  identify behavioral disorders are some of the challenges facing the  neuroimmunology, a science that studies the inflammation and  mechanisms of inflammation of the central nervous system and its  involvement in diseases such as multiple sclerosis, autoimmune  encephalitis or paraneoplastic neurological diseases. Dr. Josep  Dalmau,  IDIBAPS ICREA researcher who leads the IDIBAPS  Autoimmunity against synaptic antigens Group, is an international  leader in the study of neurology  and psychiatry and in the past 7 years  has identified a total of 8  inflammatory brain diseases. The Lancet  Neurology published an article  last week with another of his  discoveries , a neurodegenerative disease  related to sleep disturbances  hitherto unknown. Dr. Francesc Graus,  leader of Clinical and experimental neuroimmunology IDIBAPS Group and head of the Neurology at Hospital Clinic in Barcelona, is the principal investigator of the recent publication, in which also participated Dr. Joan Santamaria, neurologist Unit Sleep disorders Clinic, among others. This study has also been possible thanks to the participation of the Neurological Tissue Bank Hospital Clínic -IDIBAPS Biobank.

    Read the rest of this entry